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Integrins have been implicated as coreceptors in the infectious pathways of several nonenveloped viruses.
For example, adenoviruses are known to interact with V integrins by virtue of a high-affinity arginine-glycine-
aspartate (RGD) domain present in the penton bases of the capsids. In the case of adeno-associated virus type
2 (AAV2), which lacks this RGD motif, integrin V5 has been identified as a coreceptor for cellular entry.
However, the molecular determinants of AAV2 capsid-integrin interactions and the potential exploitation of
alternative integrins as coreceptors by AAV2 have not been established thus far. In this report, we demonstrate
that integrin 51 serves as an alternative coreceptor for AAV2 infection in human embryonic kidney 293 cells.
Such interactions appear to be mediated by a highly conserved domain that contains an asparagine-glycine-
arginine (NGR) motif known to bind 51 integrin with moderate affinity. The mutation of this domain
reduces transduction efficiency by an order of magnitude relative to that of wild-type AAV2 vectors in vitro and
in vivo. Further characterization of mutant and wild-type AAV2 capsids through transduction assays in cell
lines lacking specific integrins, cell adhesion studies, and cell surface/solid-phase binding assays confirmed the
role of the NGR domain in promoting AAV2-integrin interactions. Molecular modeling studies suggest that
NGR residues form a surface loop close to the threefold axis of symmetry adjacent to residues previously
implicated in binding heparan sulfate, the primary receptor for AAV2. The aforementioned results suggest that
the internalization of AAV2 in 293 cells might follow a “click-to-fit” mechanism that involves the cooperative
binding of heparan sulfate and 51 integrin by the AAV2 capsids.
Integrins comprise a large family of heterodimeric cell sur-
face receptors that mediate biological processes related to cell
signaling, adhesion, motility, and communication (16). In ad-
dition to these diverse roles, integrins have been exploited by a
number of viral and bacterial pathogens to gain entry into host
cells (41). In nonenveloped viruses, capsids often bind recep-
tors through projections or indentations on the surfaces that
readily enable the mimicking of native multimeric ligands (3,
14). For example, the vitronectin binding V3 and V5
integrins are internalization receptors for human adenovirus
(Ad) (28). Following the initial attachment via prominent
homotrimeric fibers, Ad is rapidly internalized into clathrin-
coated vesicles. This is thought to be mediated by penton
base association with integrin V3 and V5 through an
exposed RGD motif. The fivefold symmetry of the Ad pen-
ton base promotes the formation of an integrin ring struc-
ture that may play a key role in mediating virus internaliza-
tion (4, 37). Other examples of the role of integrins in viral
cell entry are the rotavirus, which is known to utilize inte-
grins 21, 41, and V3 for infecting intestinal cells (12,
13), and the foot-and-mouth disease virus, which utilizes an
RGD motif similar to that of Ad in binding V1, V3,
and V6 integrins (17, 18, 19).
Adeno-associated virus (AAV) is a nonpathogenic human par-
vovirus with a single-stranded DNA genome encapsidated in an
icosahedral shell of about 25 nm in diameter (2). Capsid proteins
of AAV are viral protein 1 (VP1), VP2, and VP3, with molecular
masses of 87, 73, and 62 kDa, respectively, with VP3 forming the
major structural component of the virion shell (33). Of the several
serotypes and variants that have been identified, AAV serotypes
1 to 9 are currently being developed as gene therapy vectors (11).
The diverse tissue tropism(s) of these serotypes is thought to stem
from their ability to exploit a variety of primary and secondary
receptors for transduction. For example, AAV2 has been shown
to utilize heparan sulfate (39) and AAV1, -4, -5, and -6, which
display different tropisms than that of AAV2, utilize sialic acid
with different linkage specificities for cell surface binding (20; Z.
Wu and R. J. Samulski, unpublished data). Although the initial
cell surface binding of viral capsids is often mediated through cell
surface glycosaminoglycans, many viruses require more than one
receptor to facilitate infection (36). In addition, AAV also ap-
pears to utilize several coreceptors, such as fibroblast growth
receptor 1 and hepatocyte growth receptor by AAV2 (21, 31) and
platelet-derived growth receptor by AAV5 (5), for successful cel-
lular entry.
Our lab and others have previously shown that integrin
V5 serves as a coreceptor for AAV2 infection (34, 38). In
this report, we demonstrate that AAV2 utilizes 51 as an
alternative coreceptor in 293 cells, which lack V5 integrin
(see reference 26 and references therein). More importantly,
we have identified a putative tripeptide integrin recognition
sequence within the VP3 capsid component of AAV2, which
appears to be conserved in a majority of AAV serotypes. Mo-
lecular modeling studies suggest that this integrin binding do-
main forms a surface loop located at the threefold axis of
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symmetry adjacent to residues previously implicated in binding
heparan sulfate, the primary receptor for AAV2. Our findings
support the notion that efficient infection of 293 cells by AAV2
is mediated by a sequential process involving capsid binding to
cell surface heparan sulfate, followed by 51 integrin. The
formation of higher-order molecular complexes achieved
through the cooperative binding of primary and secondary
receptors by AAV could in turn trigger coordinated events that
are essential for cellular entry.
MATERIALS AND METHODS
Plasmids, viral vectors, and biochemical reagents. The AAV2/R513A mutant
(mut) was generated by site-directed mutagenesis of the pXR2 plasmid (32)
using the QuikChange multisite-directed mutagenesis kit (Stratagene, La Jolla,
CA). The oligonucleotide primer 5-CCA AGT ACC ACC TCA ATG GCG
CAG ACT CTC TGG TGA ATC CGG-3 was synthesized at the nucleic acid
core facility at University of North Carolina (UNC)—Chapel Hill. Wild-type (wt)
or mutant pXR2 plasmid containing AAV2 Rep and Cap genes, pXX6-80 con-
taining adenovirus helper genes, and pTR-CMV-FLuc containing the firefly
luciferase gene driven by the cytomegalovirus promoter were utilized for vector
production using the triple-plasmid transfection protocol developed in our lab
(47). Viral genome titers were determined using a dot blot hybridization method
with a radiolabeled luciferase transgene probe (32). All monoclonal antibodies
(MAbs) targeted against integrin  and  subunits and the soluble 51 integrin
receptor formulated in octylglucoside were purchased from Chemicon (Temecula,
CA). Bromodeoxyuridine (BrdU) was purchased from Sigma (St. Louis, MO).
Cell culture. The HEK 293 cell line used in the production of AAV vectors
and other experiments described herein was obtained from the UNC vector core
and maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) and penicillin-streptomycin (100 U/ml). The
CHO-derived integrin 5-negative (CHOB2) and 5-reconstituted cell lines
(CHOB227) were kind gifts from Rudy Juliano. The heparan sulfate-negative
CHOpgsD cell line was obtained from the American Type Culture Collection
(Manassas, VA). All CHO-derived cell lines were maintained in -MEM sup-
plemented with 10% FBS, penicillin-streptomycin (100 U/ml), ribonucleosides,
and deoxyribonucleosides. The CS1 and CS1/5 cell lines were kind gifts from
David Cheresh with permission from Caroline Damsky. These cells were main-
tained in suspension with DMEM supplemented with 10% FBS and penicillin-
streptomycin (100 U/ml).
Solid-phase heparin binding studies. The abilities of the wt AAV2 and AAV2/
R513A mutant to bind heparan sulfate, the natural receptor of AAV2, were
determined as follows. Heparin-conjugated agarose beads (500 l; Sigma, St.
Louis, MO) were loaded onto Micro BioSpin columns (Bio-Rad, Hercules, CA)
and washed three times with 1 phosphate-buffered saline (PBS). Purified wt/
mut AAV2 particles (1010 vector genomes) were then loaded onto the column,
followed by the collection of flowthrough, three washes with PBS, and eluate
fractions at different salt concentrations. The quantification of vector genomes
that eluted in different fractions was carried out by dot blot hybridization.
Solid-phase integrin binding studies. The ability of the R513A mutation to
impair the binding of AAV2 capsids to the soluble nondenatured form of inte-
grin 51 was performed as follows. Soluble integrin 51 (5 g/ml) was pat-
terned on a nitrocellulose membrane in a 96-well format using a dot blot man-
ifold. The membrane was then washed with PBS, blocked with 10% milk in PBS,
and incubated with wt or mutant AAV2 capsids in 5% nonfat milk in PBS for 30
min at room temperature. Following three washes with PBS at room tempera-
ture, the membrane was washed and probed with A20 primary antibody (1:20
dilution in 2% milk) against AAV2 capsids for 30 min. The membrane was then
washed and incubated with anti-mouse horseradish peroxidase-conjugated sec-
ondary antibody (Pierce, Rockford, IL; 1:7,500 dilution in 2% milk) for 30 min,
and the relative binding intensities were quantified by chemiluminescence and
densitometric analysis.
Cell adhesion studies. The abilities of wt AAV2 and AAV2/R513A mutant
capsids to inhibit the adhesion of HEK 293 cells to fibronectin, the natural ligand
for integrin 51, were compared with those of monoclonal antibodies against
several integrin receptors. Briefly, confluent 15-cm plates of 293 cells were split
and allowed to recover in FreeStyle 293S (Invitrogen, Carlsbad, CA) suspension
medium overnight. Cells (5  104) were then incubated with wt/mut AAV
capsids at a high multiplicity of infection (MOI) (106) or anti-51, anti-V3,
anti-V5 antibodies (20 g/ml) for 1 h at 37°C to facilitate receptor internal-
ization/blockade. The cells were plated on fibronectin-coated 96-well plates (Bio-
Rad, Hercules, CA) in quadruplicate and allowed to adhere for 30 min at 37°C.
Wells were washed three times with PBS and fixed with 4% paraformaldehyde in
PBS for 5 min at room temperature (RT). Subsequently, 100 l of crystal violet
dye solution (0.5% wt/vol dissolved in 20% ethanol in PBS) was added to each
well, incubated for 15 min at RT, and washed three times with PBS and the cells
were incubated with 0.1% Triton X-100 for several hours at RT. The quantifi-
cation of dye uptake in 293 cells adhered to fibronectin-coated wells was per-
formed using UV absorbance spectroscopy (max 	 595 nm).
Cell surface binding and internalization studies. The ability of the AAV2/
R513A mutant or wt AAV2 to bind to the surface of HEK 293 cells was
determined as follows. Briefly, wt or mutant AAV2 capsids were incubated with
107 cells in suspension medium (MOI, 1,000) for 2 h at 4°C to allow cell surface
binding. Cells were then washed three times with PBS, and half of the samples
were incubated at 37°C for 1 h to allow internalization. The latter half of the
samples were then washed with PBS and spun down at 13,000  g for 1 min, and
the cell pellet was resuspended in 100 l trypsin-EDTA (Sigma, St. Louis, MO)
for 5 min at room temperature. Cells were then washed three times with PBS
and all cell-associated vector/genomic DNA was extracted using a DNeasy kit
(QIAGEN). The quantification of AAV genomes bound to the cell surface or
internalized in 293 cells was achieved by dot blot hybridization used previously in
determining vector genome titers.
Viral transduction assays. All transduction assays were performed by quanti-
fying luciferase transgene expression in cell lysates at 24 h postinfection with
D-luciferin (NanoLight, Pinetop, AZ) as the substrate using a Victor2 luminom-
eter (PerkinElmer, Wellesley, MA). For inhibition studies, HEK 293 cells were
preincubated with monoclonal antibodies against different integrin  and 
subunits (20 g/ml) for 1 h at 37°C to facilitate receptor blockade. In addition,
293 cells were treated with AAV2 capsids (MOI, 1,000) preincubated with
soluble integrin 51 (20 g/ml) for 1 h on ice, followed by the quantitation of
luciferase transgene expression 24 h postinfection. The CS1 cells were pretreated
with BrdU (2 M) for 48 h to promote the overexpression of integrin subtypes
(40). Subsequently, wt AAV2-Luc or AAV2/R513A-Luc vectors (MOI, 1,000)
were incubated with treated cells at 37°C in the continued presence of inhibitors/
chemicals for 24 h prior to the quantification of luciferase expression. The
CS1/5 cell line and CHO-derived cell lines were also incubated with wt or mut
AAV vectors (MOI, 1,000) at 37°C, and the transduction efficiencies were as-
sessed at 24 h postinfection.
Animal experiments. Transduction efficiencies of wt AAV2 and the AAV2/
R513A mutant in vivo (dose 1010 vector genomes) were determined, following
intramuscular administration into the hind limbs of male BALB/c mice (6 to 8
weeks of age), by quantifying luciferase transgene expression using the Xenogen
IVIS 100 imaging system. Animals were imaged 3, 7, 14, 21, and 28 days postin-
jection with a single intraperitoneal administration of D-luciferin (120 mg/kg). All
protocols were approved by the IACUC at UNC—Chapel Hill.
Molecular modeling. The location of the asparagine-glycine-arginine (NGR)
integrin recognition sequence on the VP3 domain of the AAV2 capsid was
determined by generating a three-dimensional model of a VP3 trimer using
VIPER (viperdb.scripps.edu), with the available coordinates of AAV2 (48; PDB
accession no. 1LP3) supplied as a template. Subsequent surface rendering and
mapping of the NGR loop was performed using PyMOL (www.pymol.org).
RESULTS
Alternative integrin receptor for AAV2 in HEK 293 cells.
HEK 293 cells are known to lack integrins V3/5 but con-
tain V/51 integrins (see reference 26 and references
therein). As shown in Fig. 1, monoclonal antibodies targeted
against integrin subunits 5, 1, or the 51 heterodimer
significantly inhibit the transduction of wt AAV2-Luc in 293
cells. In contrast, anti-V and anti-V5 antibodies fail to
inhibit AAV2 transduction in this cell line. Further, coincuba-
tion of the AAV2 capsid with the soluble 51 integrin recep-
tor results in an approximately 50% inhibition of luciferase
transgene expression in 293 cells. These results support the
notion that 51 integrin can serve as a coreceptor for AAV2
infection in 293 cells, which lack V5 integrin. The afore-
mentioned observations are analogous to adenovirus type 5,
which utilizes V1 as an alternative coreceptor in the absence
of integrin V3 for infection in 293 cells (26).
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Scanning the AAV capsid for integrin 51 recognition
sequences. Several integrin binding motifs have been identified
in the literature through mutagenesis and phage display studies
(23, 24, 25, 30). Among these, the high-affinity RGD motif and
the moderate-affinity NGR motif previously identified in fi-
bronectin and isolated in phage display studies are well known.
Scanning the capsid protein sequences of AAV serotypes for
such motifs and subsequent sequence alignment revealed an
NGR motif at positions 511 to 513 in the VP3 regions of a
majority of AAV serotypes (Fig. 2). Based on these findings,
we performed site-directed mutagenesis to elucidate the po-
tential role of this NGR motif in AAV capsid-integrin inter-
actions. Briefly, the AAV2/R513A mutant was engineered us-
ing a site-directed mutagenesis kit to present an NGA motif
instead of the wt NGR domain proposed to be involved in
integrin binding. This mutant AAV vector was generated suc-
cessfully by using the triple-plasmid transfection protocol, and
the genomic titers were not significantly impacted by this mu-
tation (2.5-fold less than those of wt AAV2 vectors).
Interaction of the R513A mutant with heparin and soluble
integrin 51. The heparin binding profile of the AAV2/
R513A mutant was compared with that of wt AAV2. As shown
in Fig. 3A, the elution profiles for wt and mut AAV2 deter-
mined by dot blot hybridization are identical, with both vectors
FIG. 1. Anti-integrin antibody-mediated inhibition of AAV2 trans-
duction in 293 cells. Cells grown in 24-well plates (105/well) were
incubated for 1 h at 37°C with monoclonal antibodies (20 g/ml)
targeted against different integrin subunits and heterodimers. The cells
were then dosed with AAV2-Fluc (MOI, 1,000) in the continued pres-
ence of MAbs at 37°C for 24 h prior to the quantitation of luciferase
transgene expression in cell lysates. Soluble integrin 51 (1 g/ml)
was preincubated with AAV2-Fluc particles for 1 h on ice, and 293
cells were incubated with the mixture for 24 h at 37°C prior to that
quantitation of luciferase expression. All experiments were performed
in triplicate. Gray bars depict statistically significant data in compari-
son with the control (P 
 0.05). Error bars indicate standard
deviations.
FIG. 2. Sequence alignment of the NGR motif found in the 9th type III repeat of fibronectin (25), integrin 51 binding NGR domain
identified through phage display (23, 24), and a partial section of the VP3 region of AAV serotypes performed in vector NTI. The 511-NGR-513
domain is conserved in the majority of AAV serotypes except AAV4, -5, and -11. AAV4 contains an inverse RGD (DGR) motif, also previously
identified as a low-affinity integrin binding motif. Similar residues are depicted with a black font/blue background, dissimilar residues with a black
font/white background, and conserved residues in with a red font/yellow background.
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eluting at a peak fraction of 0.4 M NaCl. These results suggest
that the R513A mutation does not alter the heparin binding
affinity of AAV2. Further, in order to demonstrate the poten-
tial interaction between the proposed NGR motif and integrin
51 in a cell-free setting, we determined the ability of the
R513A mutant to bind the soluble integrin 51 embedded in
a nitrocellulose membrane. As shown in Fig. 3B, the R513A
mutant displays a modest decrease in its ability to bind solid-
phase integrin 51 compared to that of wt AAV2. A potential
explanation for these observations is the likelihood that both
AAV2 and integrin 51 might require functional activation to
adapt their respective high-affinity conformations (15, 38, 43).
Competitive inhibition of fibronectin-integrin 51 interac-
tions. The ability of wt AAV2 and AAV2/R513A mutant cap-
sids to inhibit the adhesion of HEK 293 cells to a fibronectin-
coated substrate was compared with that of monoclonal
antibodies against several integrin receptors. As seen in Fig.
3C, the anti-51 integrin antibody, but not the anti-V3/5
antibodies, was able to block 293 cell adhesion to fibronectin-
coated wells by nearly 75%, thereby validating the expression
of the fibronectin receptor in this cell line. In competitive
inhibition studies with viral capsids, wt AAV2 capsids were
able to block 293 cell adhesion by approximately 25%. In
contrast, the adhesion of 293 cells to fibronectin in the pres-
ence of the R513A mutant was essentially similar to that of the
control, implying that mut AAV2 capsids are unable to engage
integrin 51 and compete for fibronectin binding.
Cell surface binding and internalization of the R513A mu-
tant in 293 cells. Binding and cell entry of the R513A mutant
were compared with those of wt AAV2 in 293 cells, which
express constitutive levels of heparan sulfate proteoglycans
and integrin 51 (6, 26). As seen in Fig. 4, the amount of
mutant AAV2/R513A bound to the surface of 293 cells is
2.5-fold less than the amount of wt AAV2. In addition, ap-
proximately 10% of surface-bound mutant R513A capsids are
internalized into 293 cells in contrast to surface-bound wt
AAV2, 25% of which are internalized at 1 h postinfection.
Such reduced cell surface binding and internalization of
FIG. 3. (A) Heparin binding profiles of wt and mut AAV2 particles.
Heparin-conjugated agarose beads (500 l) were loaded in MicroSpin
columns, and viral particles (1010) were allowed to bind the beads for
about 10 min at room temperature. Flowthrough, washes (1 PBS), and
eluates at different salt concentrations (in PBS) were collected, and the
number of vector genomes in each fraction was determined by dot blot
hybridization. Experiments were performed in duplicate. (B) Solid-phase
integrin 51 binding profiles of wt AAV2 and mut AAV2/R513A cap-
sids. Soluble integrin 51 (1 g/ml) was embedded in nitrocellulose
membranes under nondenaturing conditions and probed with either wt or
mut AAV2 particles in 5% milk, followed by A20 MAb (1:20 dilution),
which recognizes intact AAV2 particles. The extent of binding was quan-
titated with a horseradish peroxidase-conjugated secondary antibody by
using chemiluminescence and densitometric analysis (n 	 3; P 
 0.05).
(C) Competitive inhibition of 293 cell adhesion to fibronectin-coated
substrates. Confluent 293 cells were trypsinized and allowed to recover
overnight in suspension culture medium. Cells were then incubated with
MAbs against integrins 51, V3/5 (20 g/ml), wt AAV2, or the
AAV2/R513A mutant (MOI, 108) at 37°C for 1 h to facilitate receptor
internalization/blockade. Treated and untreated cells were then allowed
to adhere to fibronectin-coated plates for 30 min, fixed, and treated with
crystal violet solution (0.5% wt/vol in 20% ethanol in PBS). Cell adhesion
was quantitated by determining the UV absorbance of each sample at 595
nm. Gray bars indicate statistically significant data compared with that of
the control (n 	 4, P 
 0.05). Error bars indicate standard deviations.
FIG. 4. Cell surface binding of wt and mutant AAV2 particles.
Viral particles were allowed to bind 293 cells for 1 h at 4°C. The cells
were then washed three times with 1 PBS, and total cell-associated
DNA was extracted using a DNeasy kit. Vector genomes associated
with 293 cells were quantitated by dot blot hybridization. All experi-
ments were performed in triplicate. The mutant displayed a statistically
significant decrease (P 
 0.05) in binding integrin 51 and the sur-
face of 293 cells in comparison with that of wt AAV2. Error bars
indicate standard deviations.
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AAV2/R513A in 293 cells might arise due to the need for
cooperative binding of heparan sulfate as well as integrin 51
by AAV2 capsids for efficient cell entry (see Discussion for
details).
Transduction studies with the AAV2/R513A mutant. The
effect of the R513A mutation on the transduction efficiency of
AAV2 in different cell types was determined by quantifying
luciferase transgene expression at 24 h postinfection. As shown
in Fig. 5A, transgene expression in 293 cells transduced with
the R513A mutant was an order of magnitude lower than that
obtained with the wt AAV2 vector. To understand this trans-
duction-deficient phenotype further, the transduction effi-
ciency of the AAV2/R513A mutant was monitored in different
CHO cell lines exhibiting specific receptor phenotypes. The
CHOB2 cell line was isolated based on its inability to bind
fibronectin and lacks a functional integrin 51 receptor (35).
The CHOB227 cell line expresses a full-length human 5
subunit with 27 amino acids in the cytoplasmic domain and is
capable of binding fibronectin to an extent similar to that of
wild-type CHO cells (1). As shown in Fig. 5B, the ability of wt
AAV2 to transduce CHOB227 cells is significantly enhanced
compared with that of CHOB2 cells. Interestingly, the AAV2/
R513A mutant does not display a similar enhancement in
transduction efficiency despite the restoration of functional
51 integrin subunits in the CHOB2 cell line. These results
indirectly support the notion that the NGR motif is a requisite
for integrin 51-mediated transduction by AAV2.
The CHOpgsD cell line is defective in heparan sulfate bio-
synthesis and therefore does not express cell surface heparan
sulfate (7, 8). Both wt and mutant AAV2 display reduced
transduction efficiency in CHOpgsD cells. More importantly,
the R513A mutant continues to display a significantly lower
transduction compared to that of wt AAV2 in this heparan
sulfate-deficient CHO cell line. These results further support
the notion that the R513 residue is involved in interactions
other than heparan sulfate binding and is critical for AAV2
transduction.
Similar transduction studies were performed with CS1 cells,
which express immature forms of the integrin 5/V subunits
and low levels of integrin 1 (10, 40). The treatment of these
cells with BrdU has been shown to promote the adhesion of
cells to substrates, such as fibronectin and vitronectin, due to
overexpression of multiple cell surface integrin heterodimers
(40). As shown in Fig. 5C, the transduction of CS1 cells by wt
AAV2 is dramatically enhanced upon pretreatment with
BrdU. However, such an increase is not seen with the AAV2/
R513A mutant despite the enhanced cell surface expression of
multiple integrin subunits. In addition, the transduction effi-
ciency of the R513A mutant remains unchanged compared to
that of wt AAV2 in the CS1/5 cell line, which was previously
transfected with the human integrin 5 subunit (10, 44). These
results further support the notion that the NGR motif is crit-
ical for integrin-mediated transduction of different cell types by
AAV2 and might be required for interaction with alternative
integrin receptors as well. Lastly, the defective phenotype of
the R513A mutant is also seen upon the injection of the mu-
tant in skeletal muscles of BALB/c mice. As shown in Fig. 5D,
the AAV2/R513A mutant demonstrates a slower onset as well
as lower level of luciferase gene expression in muscle tissue
compared to those of wt AAV2. While these data correlate
FIG. 5. In vitro transduction profiles (luciferase transgene expression)
of wt and mut AAV2 vectors (MOI, 1,000) in (A) 293 cells; (B) CHOB2
(integrin 5 negative), CHOB227 (integrin 5 transfected), and
CHOpgsD (heparan sulfate negative) cells; and (C) CS1 cells before or
after treatment with BrdU (2 M) at 24 h postinfection. Statistical signif-
icance was established at P 
 0.05 (n 	 6). (D) In vivo transduction
profiles of wt and mut AAV vectors (dose 1010 vector genomes per
mouse) following intramuscular administration into the hind limbs of
male BALB/c mice. Images of luciferase transgene expression in vivo were
obtained using the Xenogen IVIS 100 imaging system and quantified
using Living Image (version 2.5) software. Statistical significance was
established with P 
 0.05 (n 	 4). Error bars indicate standard deviations.
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well with results from in vitro studies, the impaired transduc-
tion of the R513A mutant in skeletal muscle in vivo might arise
due to several factors, including its inability to exploit integrin
receptors and/or possibly other steps in the trafficking pathway,
such as uptake, endosomal escape, uncoating, and nuclear en-
try. In this regard, further experiments to characterize the roles
of integrins in AAV infection in vivo are warranted.
DISCUSSION
Integrin 51 is a coreceptor for AAV2 infection. Multiple
integrins have been implicated in the cellular entry pathways of
nonenveloped viruses such as adenovirus and rotavirus (28, 36,
41). The HEK 293 cell line, which is commonly utilized in the
propagation of adenovirus and the production of AAV vectors,
is efficiently transduced by AAV2. These cells lack V5, a
previously identified coreceptor for AAV2 infection (38). In
this study, we first demonstrate that integrin 51 can serve as
an alternative coreceptor for AAV2 in 293 cells. Among other
parvoviruses, erythrovirus B19 is known to utilize integrin
51 for entry into erythroid progenitor cells (43). Despite the
expression of 51 and V5 heterodimers in HeLa or A549
cells, monoclonal antibodies against V5, but not 51, are
capable of inhibiting AAV2 transduction in these cell lines (A.
Asokan and R. J. Samulski, unpublished data). Based on these
findings, it is likely that AAV2 exploits specific integrins in
different cell lines during the course of infection. Mapping
integrin receptor usage by AAV serotypes other than AAV2
could shed light on alternative pathways of AAV infection.
AAV contains a putative integrin 51 recognition se-
quence. The molecular determinants of integrin binding and
subsequent cell entry by AAV have not been determined thus
far. Previous phage display studies aimed at isolating a peptide
ligand for integrin 51 have consistently identified the well-
known, high-affinity RGD motif or a lower-affinity NGR do-
main (23, 24). The NGR sequence occurs in the 9th type III
repeat of the cell binding region of fibronectin and could con-
tribute to the interaction of fibronectin with the 51 integrin
receptor (23, 24, 25). Scanning the AAV2 capsid for such
integrin recognition sequences revealed an NGR motif at po-
sitions 511 to 513 in the VP3 region of AAV2. The NGR
domain is highly conserved except in the cases of AAV4,
AAV5, and AAV11. Interestingly, AAV4 has a DGR motif
(inverse of RGD) previously shown to be a low-affinity integrin
binding domain (23).
Based on the three-dimensional structure of AAV2, the
NGR domain is located adjacent to R585 and R588 (Fig. 6A),
which were previously implicated in heparin binding by AAV2
(22, 29). Closer examination of the protein folds reveals that
the NGR domain forms a loop between two small beta strands
and is partially exposed on the surface of the AAV2 capsid
(Fig. 6B). A preliminary biochemical characterization of
AAV2/R513A revealed that mutant and wt AAV2 particles
possess similar heparin binding affinities (Fig. 3A). These re-
sults are corroborated by two previous reports that have sep-
arately established that an arginine-to-alanine point mutation
at the 513 position in the AAV2 capsid does not affect heparin
binding (22, 29).
Interestingly, the recognition of R513A particles eluted from
the heparin column by the A20 antibody, which binds intact
AAV2 capsids (45), was diminished in comparison to that of wt
AAV2 particles postelution (data not shown). These results
suggest that the R513A mutant, unlike wt AAV2, might un-
dergo an irreversible conformational change subsequent to
heparin binding. Based on these observations, it is tempting
to speculate that conformational changes subsequent to
heparan sulfate binding could result in a greater exposure of
the NGR loop region for interaction with cell surface inte-
grin receptors. Such a scenario is also plausible with other
AAV serotypes, wherein capsid binding to their correspond-
ing primary receptors, such as sialic acid, might trigger con-
formational changes that facilitate binding of the conserved
NGR domain to integrin receptors.
The NGR motif is critical for AAV2 capsid-integrin interac-
tions. The NGR integrin binding motif was previously identi-
fied through phage display studies (23, 24). Both the NG
RAHA and fibronectin-derived ALNGREESP peptides were
found to inhibit the binding of fibronectin to solid-phase inte-
grin 51, albeit with moderate efficiency. Accordingly, the
ability of the R513A mutant to competitively inhibit 293 cell
adhesion to fibronectin-coated wells or bind solid-phase inte-
grin 51 is only moderately impaired in comparison with that
of wt AAV2 (Fig. 3B and C). Such modest differences between
the abilities of wt AAV2 and mutant AAV2/R513A particles to
interact with soluble integrin 51 were also seen during com-
petitive inhibition studies with integrin binding peptides (data
not shown). However, these modest differences become more
pronounced in a cellular setting, wherein the R513A mutation
impedes cell surface binding as well as uptake of AAV2 par-
ticles (Fig. 4). Therefore, it is likely that the R513A mutation
precludes capsid interactions with integrin 51, thereby
blocking cell entry. Further characterization of AAV2 capsid-
integrin interactions through cryo-electron microscopy and
studies with other AAV serotypes might provide structural
insight into the exact nature of the interaction between the
NGR domain and integrins. However, such studies are beyond
the scope of this report.
The NGR motif is critical for 51 integrin-mediated AAV2
transduction. The R513A mutant displays reduced transduc-
tion efficiencies in different cell types in vitro and mouse skel-
etal muscle in vivo (Fig. 5). Such a transduction-deficient phe-
notype could arise due to the inability of the mutant capsid to
bind cell surface receptors, which in turn affects the efficiency
of cellular uptake. The reduced transduction of heparan sul-
fate-deficient CHOpgsD cells by the R513A mutant supports
the involvement of receptors other than heparan sulfate in
AAV2 cell entry. These conclusions are supported by the ob-
servation that reconstituting integrin subunits by transfection
or overexpression of multiple integrin heterodimers by BrdU
treatment in Chinese hamster cells fails to rescue the defective
phenotype (Fig. 5B and C). These results support the notion
that the NGR motif might facilitate capsid interactions not
only with integrin 51 but also with alternative integrin re-
ceptors. It is noteworthy to mention that similar chemical
treatment with phorbol myristoyl acetate has been utilized to
induce 51 integrin activity in K562 leukemia cells (43). Such
high-affinity conformation of integrin was found to enhance
the transduction efficiency of parvovirus B19 in the presence of
conformation-stabilizing antibodies.
At this juncture, it is noteworthy to mention the effect of
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modification of other residues, namely N511 and G512, within
the NGR domain, on the infectivity of AAV2 capsids. An
N511D change, which conferred a DGR domain on AAV2, did
not affect transduction in vitro in 293 cells. Interestingly, the
N3D change decreased luciferase expression levels, but not
the rate of onset of gene expression in mouse skeletal muscle
in vivo (Asokan and Samulski, unpublished). These results
suggest that the DGR motif might serve as a surrogate for the
NGR domain, albeit with reduced efficiency. A recent study by
Lochrie et al. included the biochemical characterization of
G512A and G512P mutant AAV2 vectors (27). Both vectors
displayed reduced transduction compared with that of wild-
FIG. 6. (A) Three-dimensional model of an AAV2 VP3 trimer viewed down the icosahedral threefold axis of symmetry (wheat, pink, and gray).
The location of the NGR integrin recognition sequence (red) is adjacent to heparin binding residues R585/R588 (blue) located within the inner
loop. (B) Close-up view of the ribbon structure of the gray and pink monomers with the NGR motif (red) presented as a loop between two beta
strands (green). The three-dimensional model of the AAV2 VP3 trimer was generated from VIPER with the available coordinates of AAV2 (PDB
accession no. 1LP3) supplied as a template. Subsequent surface rendering was performed using PyMOL.
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type AAV2, with the G512P change affecting heparin binding
ability, possibly due to a gross change in capsid topology. In-
terestingly, the modification of the NGR domain into an RGD
motif produced empty AAV2 shells unable to package vector
genomes (Asokan and Samulski, unpublished). This phenotype
could likely arise due to the disruption of interactions between
the NGR loop and the D431-R432 region, with R432 previ-
ously described as being critical for genome packaging (46).
A model for AAV2 capsid-integrin 51 interactions leading
to cell entry. Although cell surface binding of AAV2 is medi-
ated by its primary receptor, heparan sulfate, subsequent cel-
lular uptake requires efficient interaction with a secondary
receptor (21, 31, 38, 39). It is therefore likely that the NGR
domain and amino acid residues implicated in heparan sulfate
binding are both critical for mediating AAV2 capsid-integrin
51 interactions and subsequent cell entry. A model explain-
ing the results described herein is depicted in Fig. 7. The
binding of the AAV2 capsid to cell surface heparan sulfate in
its native conformation results in a reversible conformational
change that primes the NGR domain for integrin binding. At
this time, the AAV2 particle could repeatedly bind to (and
detach from) cell surface heparan sulfate proteoglycans until
efficient engagement of the capsid with an integrin 51 re-
ceptor is achieved. Such a “click-to-fit” mechanism could then
trigger an irreversible conformational change within the capsid
and a cascade of events leading to endocytic uptake of AAV2.
Interestingly, a similar two-step mechanism has been pro-
posed for reovirus, wherein the initial interaction with its pri-
mary receptor, sialic acid, is thought to promote a reversible
conformational change that is a prerequisite for secondary
receptor interactions (9). Another interesting analogy is the
key role played by heparan sulfate in the interaction of fi-
bronectin with integrin 51. Veiga et al. have demonstrated
that integrin 51 is a facultative proteoglycan with extensive
heparan sulfate glycosylation (42). Thus, fibronectin-integrin
51 interactions, which are thought to occur primarily
through the RGD domain, appear to be complemented and
stabilized by secondary interactions with the heparan sulfate
chains on the integrin subunits and neighboring proteoglycans.
A similar cooperative binding model involving cell surface
heparan sulfate and integrin 51 could constitute the under-
lying basis of AAV2 cell entry.
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